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Abstract
Changes to islet cell identity in response to type 2 diabetes (T2D) have been reported in rodent models, but are less well
characterized in humans. We assessed the effects of aspects of the diabetic microenvironment on hormone staining, total
gene expression, splicing regulation and the alternative splicing patterns of key genes in EndoC-βH1 human beta cells.
Genes encoding islet hormones [somatostatin (SST), insulin (INS), Glucagon (GCG)], differentiation markers [Forkhead box O1
(FOXO1), Paired box 6, SRY box 9, NK6 Homeobox 1, NK6 Homeobox 2] and cell stress markers (DNA damage inducible
transcript 3, FOXO1) were dysregulated in stressed EndoC-βH1 cells, as were some serine arginine rich splicing factor
splicing activator and heterogeneous ribonucleoprotein particle inhibitor genes. Whole transcriptome analysis of primary
T2D islets and matched controls demonstrated dysregulated splicing for ∼25% of splicing events, of which genes themselves
involved in messenger ribonucleic acid processing and regulation of gene expression comprised the largest group.
Approximately 5% of EndoC-βH1 cells exposed to these factors gained SST positivity in vitro. An increased area of SST
staining was also observed ex vivo in pancreas sections recovered at autopsy from donors with type 1 diabetes (T1D) or T2D
(9.3% for T1D and 3% for T2D, respectively compared with 1% in controls). Removal of the stressful stimulus or treatment
with the AKT Serine/Threonine kinase inhibitor SH-6 restored splicing factor expression and reversed both hormone
staining effects and patterns of gene expression. This suggests that reversible changes in hormone expression may occur
during exposure to diabetomimetic cellular stressors, which may be mediated by changes in splicing regulation.
Introduction
A reduction in beta cell mass occurs during the progression of
type 2 diabetes (T2D) and has been attributed to net enhance-
ment of the rate of beta cell death (1,2). It is increasingly appar-
ent, however, that changes in the differentiation status of beta
cells may also be a contributory factor (3,4). Studies in mouse
models of diabetes have described a gradual process of transdif-
ferentiation from beta cells to alpha (5,6), and dedifferentiation
to earlier progenitor cell types has also been reported (4,7).
Beta to delta cell transdifferentiation has also been reported by
lineage tracing in mouse islets in response to immunological
stimuli (8). Data fromhuman pancreas are scarce, but the limited
information available suggests that similar changes in differen-
tiation status may also occur in humans (9,10).
Maintenance of beta-cell identity is determined by a
tightly regulated transcriptional network, consisting of proteins
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encoded by the Pancreatic and Duodenal Homeobox 1 (PDX1),
Forkhead Box O1 (FOXO1), NK2 Homeobox 2 (NKX2-2), MAF BZIP
Transcription Factor A (MAFA), NK6 Homeobox 1 (NKX6-1) and
Paired Box 6 (PAX6) genes amongst others. Most of these do not
display specific expression in beta cells but are also expressed
in other pancreatic islet cell types; their role in cell identity
definition is likely to involve the relative balance of expression
(5,11,12).Among these, the FOXO1 gene, a downstreameffector of
AKT signalling in beta cells (13), has been demonstrated to play
a specific role in the maintenance of beta cell differentiation
status in mice (3). In addition to its role in regulation of
beta cell plasticity (14) and in stress responses (15), FOXO1
has also been demonstrated to regulate alternative splicing
(a powerful interface between cell identity and cell stress) by
moderation of splicing factor expression in human primary
fibroblasts (16).
The cellular microenvironment created by diabetes is
stressful for beta cells (17), and elevated glucose levels have
been linked to reduced expression of nodal genes within the
transcriptional network that controls beta cell identity at the
level of total gene expression (18). Changes to beta cell differen-
tiation status also occur in response to chronic hyperglycaemia
(7,19). Exposure of beta cells to the saturated fatty acid, palmitate
or to pro-inflammatory cytokines has also been shown to
induce widespread changes to the beta cell transcriptome
(20,21). Altered beta cell identity may occur as a protective
mechanism in response to a stressful extracellular milieu, with
cellular plasticity serving to protect beta cells which might,
otherwise, be lost via apoptosis.As such, this reversible plasticity
may allow for later re-differentiation should the extracellular
environment become more conducive (7). Such effects could be
relevant to all beta cells but they may be particularly important
for ‘hub cells’ within islets,which are known to bemore sensitive
to insult than other beta cell subsets, resulting in beta cell
failure (22,23). A recent study has also shown that beta cells
are heterogeneous and can be ordered into three major states
characterized by relative insulin (INS) expression and ER stress
levels. High ER stress and low INS gene expression levels relate
to a more immature beta cell state that doesn’t itself drive
dedifferentiation but thatmay render themvulnerable to further
insult (24).
We hypothesized that exposure to the cellular stressors that
accompany the development of diabetes may cause disrupted
regulation of key genes involved in the maintenance of beta
cell identity, leading to changes in beta cell fate. We exposed
human EndoC-βH1 beta cells in culture to a variety of diabetes-
relevant cellular stressors and demonstrated alterations in the
expression patterns of several key beta cell genes involved
in the control of cell fate and cell identity and also in those
controlling alternative splicing. Changes to the splicing patterns
of 26% of genes were also apparent in human islets from donors
with diabetes compared with non-diabetic controls. These
changes were accompanied by alterations in hormone staining
both in vitro and in ex vivo. These changes were reversible
upon removal of the stressful stimulus or by moderation
of splicing factor expression. Our observations suggest that
altered splicing regulation and dysregulated splicing induced
by cellular stress may influence the identity and proportions of
hormone-expressing cells in human islets. Targeting splicing
regulation may prove a fruitful avenue of investigation for
future interventions to maintain beta cell differentiation in
diabetes.
Figure 1. Effects of cell stresses on total gene expression of genes with roles in beta cell differentiation or function. Volcano plots demonstrating the most dysregulated
genes in response to 24 h treatment with cellular stressors associated with a T2Dmicroenvironment. Volcano plots are illustrative of the numbers of genes dysregulated
by cell stresses from qRTPCR data. The y axis shows −log10 of P-value; x axis shows differences in mean logged relative quantification units between treatments and
controls. Bonferroni corrections were performed to take account of the number of time points but not for the number of genes in the target panel as these are a priori.
Upper line infers the Bonferroni multiple testing limit. The lower dotted line gives nominal significance. (A) 25 mM high glucose; (B) 2.5 mM low glucose; (C) Hypoxia
<3% O2; (D) 0.5 mM PI; (E) Cytokines TNFα, IL1β, INFγ; (F) 0.5 mM Tunicamycin for ER stress.
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Figure 2. (A) Effects of cell stresses on splicing factor expression.Modified Manhattan-style plot corrected for direction of effect showing the effects of cellular stressors
on splicing factor expression. The y axis shows −log10 of P-value with direction of effect from data generated by TLDA cards. Bonferroni corrections were performed
to take account of the number of treatments but not for the splicing regulators as these are known to be affected by cell stresses in a number of other cell types (16).
Upper line infers the Bonferroni multiple testing limit. The lower dotted line gives nominal significance. Blue circles 25 mM high glucose. Green squares, 2.5 mM low
glucose; Red diamonds, < 3% O2; Purple triangles, 0.5 mM PI; Orange triangles, cytokines. Upper line infers the Bonferroni multiple testing limit. The lower dotted line
gives nominal significance. (B) Effects of cell insult treatments on alternatively spliced gene expression. Modified Manhattan-style plot corrected for direction of effect.
The x axis refs to the ratio of alternatively expressed isoforms at each locus from data generated by qRTPCR. Ratio was calculated by dividing expression of variants by
expression of canonical transcripts. The y axis shows −log10 of P-value with direction of effect. Bonferroni corrections were performed to take account of the number
of time points but not for the genes in the target panel as these are a priori. Upper line infers the Bonferroni multiple testing limit. The lower dotted line gives nominal
significance. Blue circles, 25 mM glucose; green squares, 2.5 mM glucose; red diamonds, < 3% O2; purple triangles, 0.5 mM PI; pink inverse triangles, cytokines; orange
hexagons, 0.5 mM. (C) The proportion of alternatively spliced genes demonstrating dysregulation in islets from donors with T2D. Data generated by Clariom D pico
array. (C1) Pie chart showing the cellular and molecular functions of alternatively spliced transcripts that display dysregulated splicing patterns in islets from donors
with T2D compared with matched controls. (C2) Pie chart showing the nature of splicing events that are dysregulated in islets from donors with T2D compared with
matched controls.
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Figure 3. The effects of cell stressors to hormone expression in human beta cell line EndoC-βH1. (A) Immunofluorescence cytochemistry showing gain of SST expression
in cells treated with 25 mM high glucose. Cells were treated for 24, 36 and 48 h and showed gains of SST expression at all time points. There was no increase in the
proportion of cells gaining SST expression at later time points. Representative image panels from 36 h time point. (A) Panels 1 and 2 refer to treatment with 5 mM
glucose as a control. Panels 3 and 4 refer to treatment with 25 mM glucose to mimic hyperglycaemia. The identity of the antibody used to stain is indicated in each
panel. Of those cells that gained SST positivity, 17% were dual hormone positive. There were accompanying changes in the expression of INS and SST (P= 0.035, mean
difference 0.223 and P= 0.004 mean difference 0.211, respectively). (B) Timecourse of SST positivity in cultures of EndoC-βH1cells treated with high glucose (25 mM).
(C) The number of SST-positive cells in cultures of EndoC-βH1 cells treated with high glucose (25 mM), PI 0.5 mM, Hypoxia (3% O2), Cytokines (TNFα [1000 U/mL], INFγ
[750 U/mL] and IL1β [75 U/mL]), Tunicamycin (0.5 mM) or oleic acid (0.5 mM).
Results
Key beta cell fate and function genes show disrupted
expression in response to cell stress stimuli in
EndoC-βH1 cells
We tested the total expression levels of a panel of 31 preselected
genes encoding hormones, determinants of beta cell identity or
function and markers of cell stress in response to treatments
designed to mimic aspects of diabetic pathophysiology. Large-
scale changes in the expression of the majority of these genes
were noted in response to all treatments across all time points
(Supplementary Material, Table S1; Fig. 1A–F). Notable amongst
these were MAFA, PAX6, NEUROD1, NKX2-2, PDX1, NKX6-1 and
PAX4, which are known to form an interacting network. All of
these were responsive to either 25 mM D-glucose or 0.5 mM
palmitic acid (PI). PAX6, NKX2-2, PDX1, NKX6-1 and PAX4 were
similarly responsive to hypoxia. Differences in expression were
also evident for HES1, SRY box 9, NGN3 NANOG and POU5F1
genes, which are markers for cellular plasticity. Markers of cel-
lular stress including DNA damage inducible transcript 3, ARNT
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Figure 4. Hormone staining patterns of donor islets from controls or individuals with T2D. (A) Panels 1–4 are representative immunofluorescence images from human
donor pancreatic tissue from controls (panels 1 and 2) and from cases of T1D compared to matched controls (panels 3 and 4). The identity of the antibody used to stain
is indicated in each panel. (B) Panels 5–8 are representative immunofluorescence images from human donor pancreatic tissue from controls (panels 5 and 6) and from
cases of T2D compared to matched controls (panels 7 and 8). (C) Graph showing interquartile range from delta cell counts for individuals without diabetes and patients
with either T1D or T2D. We found a significant increase in the number of SST-positive cells in patients with either T1D INS-containing islets and INS-deficient islets
(P= 3.0×10−6) or T2D (P=2.20× 10−4) compared to their respective controls.
andMYC also showed altered expression patterns under all con-
ditions tested. Similar results were achieved following treatment
with the generalized cellular stressor tunicamycin (Supplemen-
tary Material, Table S2).
Changes to the expression of splicing factors and beta cell splicing
patterns in response to cell stress stimuli in EndoC-βH1 cells. We
assessed the responses of genes encoding splicing factor genes,
given their role in mediating the relationships between cell and
environment (25,26). Several splicing factors, notably the genes
encoding HNRNPA2B1, AKAP17A, PNSIR, serine arginine -rich
splicing factor (SRSF1), SRSF2, SRSF3, SRSF6 and LSM14A demon-
strated dysregulated expression in response to treatment with
cytokines, hypoxia, high/low glucose or altered lipids (Fig. 2A;
Supplementary Material, Table S3). To determine whether these
changes had functional significance, we also assessed the
splicing patterns of key beta cell genes. Genes were included for
analysiswhere theywere known to produce alternatively spliced
isoforms with functionally different roles in beta cell function or
differentiation status that we could identify uniquely. A total of
3/5 genes fitting these criteria (PAX6, PTPN1 and POU5F1/OCT4)
demonstrated changes in the ratio of alternatively expressed
isoforms in response to treatment (Fig. 2B; Supplementary
Material, Table S4).
26% Of alternative splicing events demonstrate dysregulation in
human islets form donors with T2D. Assessment of
transcriptome-wide patterns of alternative splicing demon-
strated that of 47 944 splicing events detected in coding genes,
12 438 (26%) of splice sites in 6209 genes demonstrated altered
usage (gene list available on request). Pathways analysis revealed
that 6209 genes demonstrated altered splicing events in T2D
islets, and these were clustered in 196 pathways that grouped
into 11 cellular functions. Of these, gene regulation amounted
to the largest share at 17.65% of all pathways (Fig. 2C1 and
C2). Gene ontology (GO) analysis for biological processes and
molecular function showed the top results were RNA metabolic
process and RNA binding, respectively (Supplementary Material,
Table S5).
Metabolic and ER stress is associated with gain of SST positivity
in EndoC-βH1 cells. We quantified the effect of treatments
designed to mimic the islet milieu in diabetes on cell identity in
EndoC-βH1 cells cultured in vitro. A small (∼5%) but consistent
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Figure 5. Rescue of phenotype by restoration to normal culture conditions. This figure illustrates the rescue of beta cell phenotype in EndoC-βH1 cells treated with
25 mM glucose for 24 h followed by restoration to 5 mM glucose culture conditions for 72 h. (A) Panels 1 and 2 are representative immunofluorescence images from
untreated EndoC-βH1 cells. (B) Panels 3 and 4 are representative immunofluorescence images from EndoC-βH1 cells treated with 25 mM glucose for 24 h. (C) Panels
5 and 6 are representative immunofluorescence images from EndoC-βH1 cells treated with 25 mM glucose for 24 h but then restored to 5 mM glucose for 72 h. The
identity of the antibody used to stain is indicated in each panel. Immunofluorescence image panel. (B) The graph gives the total gene expression levels, generated by
qRTPCR, for genes previously demonstrating dysregulated expression in response to glucose under treated and rescued conditions. (C) The graph gives the isoform
expression levels for genes previously demonstrating dysregulated splicing in response to glucose under treated and rescued conditions.
and statistically robust increase in the number of somatostatin
(SST)-positive cells was noted in EndoC-βH1 cell cultures in
response to incubation with elevated glucose levels (both D- and
L-glucose) for 24 h. Control cells, incubated in 5.5 mM D-glucose,
showed no evidence of SST immunopositivity (P=9.1×10−5,
Fig. 3A). The proportion of SST-positive cells remained stable
over longer periods of culture, and no evidence of increased rates
of cell death was seen in cells incubated under hyperglycaemic
conditions (Fig. 3B). An increase in SST-positive cells was also
noted in response to PI, hypoxia, pro-inflammatory cytokines
and tunicamycin (P=5.2× 10−5, P=4.2×10−5, P=4.0×10−3 and
P=5.0× 10−3, respectively; Fig. 3C). Conversely, no such increase
was seen in response to oleic acid (P=0.343), although cells
exposed to both PI and oleic acids concurrently responded
in a similar manner to those treated with palmitate alone
(P=0.003). No evidence of increased glucagon (CGC) expression
was noted in control or treated EndoC-βH1 cells at the protein
level although a rise in GCGmessenger ribonucleic acid (mRNA)
(and that encoding the transcription factor ARX) was evident
in response to some treatment conditions. No change in the
expression of HHEXmRNA transcripts was noted.
Pancreatic sections from donors with T1D or T2D demonstrate
increased numbers of SST-positive cells. To determine if the
effects we had noted in EndoC-βH1 cells in vitro were also
recapitulated in human pancreas,we determined the proportion
of different endocrine cell types in islet preparations from
donors with long duration type 1 diabetes (T1D) or T2D and in
control islets.We identified a significant increase in SST-positive
(delta) cell area in tissue sections from patients with either long
duration T1D or T2D compared to control islets. The total SST-
positive area in in situ islets from T1D or T2D donors compared
to control islets was 17069.9 µM (3%) v/s 6166.24 µM (1%) for T2D
(P=2.47×10−9) and 31713 µM (9.3%) v/s 7360 µM (1% of islet
area) for T1D (P=2.1×10−6) (Fig. 4A and B; n=10 images for 5
cases and 5 controls). An assessment using direct counting of
cells rather than staining area also showed significant increases
in the number of delta cells (Fig. 4C). There was no increase in
the total islet cell count. Pancreatic islets from donors with long
duration T1D contained a median number of 8 delta cells out
of a total cell count of 62 (IQR=6) compared with 4.5 delta cells
(IQR=3) out of a total cell count of 67 for age and sex-matched
controls (P=3.0× 10−6). Similarly, pancreatic islets from donors
with long duration T2D contained a median number of 8.5 delta
cells (IQR=6) out of a total cell count of 77 (IQR=6) compared
with 5 delta cells (IQR=3) out of a total cell count of 71 for age and
sex-matched controls (P=2.2×10−4; Supplementary Material,
Table S6).
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Figure 6. Hormone staining and gene expression changes following restoration of splicing factor expression using the AKT inhibitor SH-6. This figure illustrates
the rescue of beta cell phenotype in EndoC-βH1 cells following restoration of splicing factor expression to that seen in normal glucose conditions. (A) Panels 1–4 are
representative immunofluorescence images from untreated EndoC-βH1 cells. Panels 5–8 are representative immunofluorescence images from EndoC-βH1 cells treated
with 25mM glucose for 24 h. Panels 9–12 are representative Immunofluorescence images from EndoC-βH1 cells treated with SH-6 alone. Panels 13–16 are representative
immunofluorescence images from EndoC-βH1 cells treated with 25 mM glucose and SH-6 for 24 h. The identity of the antibody used to stain is indicated in each panel.
(B) Graph showing the number of SST-positive cells under different culture conditions.
Changes in hormone staining and beta cell expression patterns
are reversible upon restoration of homeostatic conditions in
EndoC-βH1 cells. To determine whether the changes in cell
identity and gene expression patterns we have observed
were permanent or reversible, we exposed EndoC-βH1 cells to
cellular stressors for 24 h but then returned the cells to control
conditions for 72 h prior to assessment. Following treatment
with either high glucose or tunicamycin, we noted an increase
in the number of SST-positive cells compared to controls
(Fig. 5A; P=3.69×10−9 and P=1.3× 10−4) and dysregulation
of splicing ratios of candidate alternatively spliced genes
(Fig. 5B and C; Supplementary Material, Table S7). Following
return to control conditions, the number of SST-positive cells
was indistinguishable from zero time point controls (Fig. 5A;
P=0.568 and P=0.643), and patterns of alternative splicing
were restored (Fig. 5B and C; Supplementary Material, Table S7)
indicating that the treatment induced changes we noted were
reversible.
The AKT inhibitor SH-6 restores splicing factor expression and
abolishes SST positivity in EndoC BH1 cells. The AKT pathway
has previously been suggested to have a role in regulation of
splicing and splicing factor activity (26). Therewas no emergence
of SST-positive staining in cells treatedwith low concentration of
the AKT inhibitor SH-6 alone, whereas cells treated with 25 mM
glucose demonstrated an increase in SST positivity similar to
that we observed previously (P=0.0004). EndoC-βH1 cells treated
with SH-6 and subsequently exposed to 25 mM glucose for 24 h,
however, showed no increase in the number of SST-positive cells
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compared to 5 mM glucose controls (Fig. 6A and B). This effect
was also noted at the level of splicing factor expression and
alternative splicing (Supplementary Material, Table S8).
Discussion
In other cell types, alternative splicing forms a key part of the
cellular defence against stress by adjusting the transcriptomic
output of the cell to meet its new requirements (27). The cel-
lular microenvironment induced by diabetes is stressful to beta
cells, which may respond by either undergoing apoptosis (1,2)
or by altering their differentiation state (10,28,29) resulting in an
overall loss of beta cell mass. We hypothesized that exposure
to diabetes-related cellular stresses may disrupt the normal
patterns of splicing occurring in beta cells, potentially leading
to changes in beta cell fate or function. We report here that
human EndoC-βH1 beta cells treated with diabetes-related cel-
lular stressors, such as altered glucose, fatty acids, cytokines or
hypoxia or with the ER stress inducer tunicamycin, displayed
altered expression of genes involved in splicing regulation, as
well as altered expression of important genes for cell fate or
function in vitro. Furthermore, islet samples from patients with
T2D diabetes displayed large-scale disruption to transcriptome-
wide splicing patterns, with over a quarter of genes demonstrat-
ing splicing alterations. The main class of genes with altered
splicing comprised genes themselves involved in mRNA pro-
cessing and regulation of gene expression. These transcriptomic
changes were accompanied by an increase in the number of SST-
positive cells in cultured EndoC-βH1 cells, an observation that
was also evident in islet sections fromhuman donorswith either
T1D or T2D. Similar effects were also noted when cells were
exposed to L-glucose, suggesting that the response may occur in
response to an osmotic stress and also that changes to beta cell
differentiation statuswere not restricted tometabolic stress.The
monounsaturated fatty acid oleate, a fatty acid that is not known
to induce metabolic stress in human beta cells (30), elicited no
response. The changes in cell hormone staining were reversible
by either removal of the cellular stress or by resetting splicing
factor expression to their previous level using small molecule
moderators of splicing factor expression. These observations are
consistent with previous reports that stress-related changes in
beta cell differentiation status are modifiable once the noxious
stimuli are removed (18).
Beta cell differentiation status is influenced by a transcrip-
tional network of genes including PAX6, PDX1, NEUROD1, NKX2-
2, NKX6-1, MAFA, PAX4 and FOXO1 (31,32), which demonstrated
altered expression in our work. As the majority of these genes
are also expressed in the other islet cell types, it is likely that
beta cell maturity and identity is probably conferred by the
subtle balance of these regulators.PDX1 typically exhibits shared
expression patterns across beta and delta cells; however, here
we found reduced expression of PDX1 with concomitant gain
of SST gene and protein expression, which suggests they may
not be fully committed to a delta cell phenotype (33) and thus
not display all the expected delta cell markers. Similarly, there
was also no significant gain in the expression of the delta cell
marker HHEX, which is required for delta cell differentiation
(34). Further, FOXO1 is a key player in determination of beta cell
fate and function; targeted disruption of this gene in mouse
embryos is known to result in cell fate changes in developing
mouse pancreas (13). It is also a pivotal part of the beta cell
stress response (5,35). FOXO1 and PDX1 have also been shown
to be mutually exclusive in the nucleus (5). In recent years,
a new role for FOXO1 has also been identified as a regulator
of the genes involved in alternative splicing decisions in some
human cell types in the context of cellular senescence (16).
Targeted knockdown of the FOXO1 gene, or the use of inhibitor
SH-6 that regulates FOXO1 activity, was able to restore splicing
factor expression to levels seen in younger cells and restore
cells to a younger phenotype (16). Alternative splicing has been
well documented as a response to cellular stress (27). FOXO1
thus forms an interface between cell stress, alternative splic-
ing and cell fate decisions. We have demonstrated here that
transcripts encoding the serine arginine rich and heterogeneous
ribonucleoprotein particle (HNRNP) genes,which encode positive
and negative regulators of alternative splicing, respectively,were
dysregulated in treated cells, as were patterns of alternative
splicing for a limited number of functionally relevant candidate
genes tested. We also identified that at the transcriptome-wide
level, 26% of all splicing events were altered in human primary
islets from donors with T2D, indicating that this observation
may also hold true in vivo. Interestingly, one of the predominant
pathways demonstrating splicing dysregulation included those
themselves involved in RNA metabolism and RNA processing.
Although dysregulation of splicing regulators was not seen at
the level of total gene expression as changes are likely cell type-
specific and signal therefore diluted by the presence of other
cell types, there were changes in the splicing patterns of these
genes. This is particularly pertinent in that splicing factor genes
are primarily themselves regulated by alternative splicing (36).
Similar results have been previously reported for other diabetes-
relevant tissues such as adipose tissue (37). In support of the
theory that disrupted splicing may underpin the cell identity
changeswe see, restoration of splicing factor expression to levels
consistent with control cells using the AKT inhibitor SH-6,which
is known to influence splicing factor expression (16), abolished
the emergence of the SST-positive cell population, even in the
presence of high glucose. Although SH-6 has not previously been
shown to inhibit AKT in EndoC-βH1 cells, it has been shown to
do so in another beta cell line RINm5F (38).
There are several potential explanations for the emergence
of an SST-positive population. Firstly, this could arise from pro-
liferation of a population of delta-like cells or progenitor cells
in the cultures, or in the primary islets. It is also possible that
progenitor cells may be present in the culture but are push-
ing the cells to an INS-positive rather than SST-positive fate.
However, the lack of SST-positive staining in the absence of
cell stress in the untreated EndoC-βH1 cell population suggests
that expansion of a progenitor or delta cell population is an
unlikely explanation for the emergence of SST positivity. Simi-
larly, immunofluorescence data from the islets of patients with
T2D showed no increase in total cell counts, which suggests
that increased numbers of SST-positive or INS-positive cells
may not be the result of expansion of a small pool of pro-
genitor cells. Another explanation is that a proportion of the
beta cellsmay have undergone beta to delta transdifferentiation.
This phenomenon has been reported previously in the mouse,
where beta-to-alpha cell transitions have been documented (5,6).
The factors underlying apparent species differences may arise
because of differences in islet architecture, gene expression and
glucose sensing between rodent and human (39), but may also
reflect profound differences in mRNA processing between these
species since only 30% of splicing events are conserved between
mice and humans (40).
We acknowledge that our study has limitations. Firstly, the
changes in cell identity were observed in only a small proportion
of the total cell population. The reasons for this are unclear
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but appear to be unrelated to the time of incubation since the
response occurred very quickly (within 24 h) andwas then stable
for several days in the continued presence of the stressor. One
possibility is that the cultures are heterogeneous and that a
small population of cells is more susceptible to stress-induced
plasticity than the majority. It would be interesting to determine
whether this putatively ‘plastic’ cell population shares features
with cells such as those identified as ‘hubs’ in intact islets since
these also display a greater degree of plasticity than other beta
cell sub populations (41–44).While it may also be that the EndoC
βH1 cells line is contaminatedwith progenitor cells, as discussed
above, the data from the rescue experiments might suggest that
this is not the case, given the absence of SST positivity during
normal culture conditions.
We also acknowledge that we have not conducted an exhaus-
tive survey of splicing changes in the treated cells. The het-
erogeneous nature of the treated cultures means that only the
largest effects would have been revealed by transcriptome-wide
analysis. To circumvent this, it would be necessary to sort the
SST-positive cells from their unchanged neighbours. This is a
technically demanding task in EndoC βH1, which does not grow
well in low cell densities, and may be susceptible to shear stress
(whichmay confound our findings). SST is also not a cell surface
marker, rendering fluorescence-activated cell sorting problem-
atic. Taking into account these challenges, we opted to query
transcriptome-wide splicing changes related to the presence
of T2D in primary human islets, where we demonstrate that
dysregulated splicing is clearly present.
We propose that our data are consistent with a model in
which the appearance of an SST-positive subpopulation can
appear in response to the imposition of cellular stress both
in vitro and ex vivo, and we postulate that this may reflect
dysregulation of splicing factor genes with consequent changes
to splicing patterns that may be mediated by altered activation
of AKT signalling and changes to FOXO1 activity. This work is,
to our knowledge, the first demonstration of the emergence
of SST positivity in human beta cells that may be specifically
associated with changes in the regulation of mRNA splicing.
Without lineage tracing experiments, which require expansion
in non-human lines and are not trivial whenusing humanmodel
systems (45), it is not possible to infer that these changes we
observed are directly due to beta to delta transdifferentiation.
However, the consequence of the changes we observed may, at
the molecular level, result in the altered expression of key genes
involved in cell fate decisions. Targeting splicing patterns for
therapeutic benefit is now an enticing possibility with several
approaches already in clinical trials (46). We have shown that
differentiation status in beta cells can be influenced by targeting
splicing decisions, and a deeper understanding of the specific
points at which such interventions could be focused might
confer benefits for diabetes therapy in the future.
Materials and Methods
Culture and treatment of EndoC-βH1 cells
EndoC-βH1 cells at Passage <25 were seeded in 24-well plates
at a density of 6.0× 105 cells/ml and maintained according to
a modified humanized culture protocol as previously described
(47) for 72 h prior to treatment. For assessment of the effects of
altered glycaemia, cells were treated with 2.5 mM and 25 mM
D- or L-glucose for 24, 36 or 48 h. Controls were maintained in
5 mM glucose media. For assessment of the effects of oxygen
levels, cells were grown in 1%, 3% or 21% O2 for a period of
24, 36 or 48 h. For assessment of the effects of altered lipids,
cells were treated with 0.5 mM PI, 0.5 mM oleic acid or 0.5 mM
PI/0.5 mM oleic acid for 12, 24 and 48 h. To determine the effects
of pro-inflammatory cytokines, cells were treated with TNFα
(1000 U/mL, INFγ (750 U/mL) and IL1β (75 U/mL) for 12, 24 and
36 h. For assessment of the effects of Endoplasmic reticulum
(ER) stress, cells were treated with 0.5 mM Tunicamycin for 24 h.
Each treatment was carried out in three biological replicates,
along with vehicle-only controls. Where cells were being used
for subsequent immunofluorescence experiments they were
cultured on 12 mm diameter coverslips and treated according
to the conditions described above before being fixed with 4%
paraformaldehyde.
Immunofluorescent characterization of EndoC-βH1
cells in vitro
The expression of mature beta cell markers, as well as islet cell
hormones in EndoC-βH1 cells grown as described above, was
assessed using co-immunofluorescent microscopy. Briefly, fol-
lowing treatment, cellswere fixedwith 4%paraformaldehyde for
15 min at 4◦C. Primary antibodies to SST and GCG were diluted
in phosphate buffered saline with 0.1 M Lysine, 10% donor calf
serum, 0.02% sodium azide and 0.02% Triton X-100 (ADST), to
permeabilize the cell membranes and incubated overnight at
4◦C. Primary antibodies were visualized using species specific
highly cross-absorbed secondary antibodies (Invitrogen, Paisley,
UK) diluted in ADST at 1/400 and incubated for 1 h at room
temperature. Sequential staining was then performed with
an antisera raised against INS (Supplementary Material, Table
S9) diluted in ADST for 1 h, followed by a goat anti guinea-
pig Alexa Fluor 555 along with 4’,6-diamidino-2-phenylindole
(DAPI) (Sigma-Aldrich, Steinheim, Germany; 1 µg/ml) for 1 h.
Slides were visualized using a Leica AF6000 microscope (Leica,
Milton Keynes,UK) and processed using the standard LASX Leica
software platform. Ten randomly selected images were taken for
each of the three biological replicates. Details of all antibodies
are provided in Supplementary Material, Table S9.
Immunofluorescent characterization of human
pancreatic tissue sections from patients with T1D or
T2D
Immunofluorescence staining was used to determine the
expression of islet cell hormones in formalin-fixed paraffin
embedded pancreatic sections from individuals with long
duration T1D, long duration T2D and individuals without
diabetes from the Exeter Archival Diabetes Biobank [http://
foulis.vub.ac.be/ or the network of Pancreatic Organ Donors with
Diabetes (nPOD) https://www.jdrfnpod.org/] (Supplementary
Material, Table S10). The majority of samples were taken from
the pancreatic body, rather than the head or tail. All samples
were studied with ethical approval (WoSREC4; 15/WS/0258).
Following dewaxing and rehydration, pancreas sections were
subjected to heat-induced epitope retrievalin 10 mmol/l citrate
buffer (pH 6). The sections were then sequentially probed
with antisera to SST, CGC and INS (Supplementary Material,
Table S9) that were detected using species specific highly
cross-absorbed secondary antibodies conjugated with fluo-
rescent dyes (Invitrogen; Supplementary Material, Table S9).
Cell nuclei were stained with DAPI. Slides were visualized
using a Leica AF6000 microscope (Leica) and processed using
the standard LASX Leica software platform. Quantification of
pancreatic endocrine cells types within the islet was achieved
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firstly by assessing the SST staining positive area as a percentage
of total islet area between T1D/T2D patients and controls as
described by others (48). To account for differences between the
total islet area of T1D or T2D cases and their respective controls,
total SST-positive areas were normalized to the global geometric
mean of all samples. Secondly, the effects of diabetes status on
endocrine cell types were assessed by counting the number of
delta cells compared to the total islet cell count. Ten randomly
selected images from seven cases and controls were taken for
T1D and from five cases and controls for T2D. Areas of SST,
INS and CGC staining were selected and measured using
Image J (49).
RNA extraction, reverse transcription and assessment
of total gene expression in EndoC-βH1 cells
EndoC-βH1 cells were washed in Dulbecco’s phosphate buffered
saline before RNA extraction using TRI® reagent to harvest RNA
(Sigma-Aldrich). RNA concentrations were adjusted to 100 ng/µL
prior to reverse transcription. Synthesis of cDNAwas carried out
using Superscript® VILOTM cDNA synthesis kit (Thermo Fisher,
Foster City, USA) according to manufacturer’s instructions. Gene
expression levels were measured in treated and untreated
EndoC-βH1 cells by quantitative real-time PCR (qRTPCR). A panel
of 31 a priori target genes was selected on the basis that they had
known roles in either beta cell fate or function, were markers
of cell stress or were markers of other pancreatic endocrine cell
types (Supplementary Material, Table S11). Endogenous control
genes (PPIA,UBC,HPRT1, GUSB, B2M and IDH3B) were empirically
selected for stability in response to treatment. qRTPCR reaction
mixes included 2.5 µL Taqman® Universal PCR mastermix II
(no AmpErase® UNG) (Thermo Fisher, Waltham, MA, USA),
1.75 µL dH2O, 0.5 µL cDNA and 0.25 µL Taqman® gene assay
(Thermo Fisher) in a 5 µL reaction volume. Cycling conditions
were 50◦C for 2 min, 95◦C for 10 min and 50 cycles of 15 s at
95◦C for 30 s and 1 min at 60◦C. Reactions were carried out in
three biological replicates and three technical replicates. Assay
identifiers are given in Supplementary Material, Table S11. The
relative expression of each test transcript was determined by
the comparative Ct approach. Expression levels were calculated
relative to the geometric mean of the endogenous controls, but
also to the global mean of expression across all transcripts
tested (as one would with an array), which was empirically
determined not to vary across test conditions to provide a
robust baseline. Expression levels were normalized to the
median level of expression seen in untreated EndoC-βH1 cell
controls. Differences in gene expression levels between mock-
treated and treated EndoC-βH1 cells were compared to the same
time point controls for each condition and investigated for
statistical significance by t-test carried out using SPSS version
23 (IBM, North Castle, NY, USA). Data were presented as means±
standard error of mean differences (S.E.D.).
Determination of splicing factor expression in
EndoC-βH1 cells
Splice site usage and thus patterns of alternative splicing are
determined by the relative balance of SRSFs (splice site acti-
vators) and heterogeneous nuclear ribonucleoprotein particles
(splice site inhibitors) at each splice site (50). Splicing factor
assay IDs are given in Supplementary Material, Table S12. The
expression levels of 20 splicing activator or splicing inhibitor
genes was quantified in EndoC-βH1 cells using Taqman® Low
Density Array (TLDA) on the Quantstudio 12 K Flex system.
Cycling conditions were 1 cycle each of 50◦C for 2 min, 94.5◦C for
10 min and then 40 cycles of 97◦C for 30 s and 57.9◦C for 1 min.
The reaction mixes included 50 µL Taqman® Fast Universal PCR
Mastermix (Life Technologies, Foster City, USA), 30 µL dH2O and
20 µL cDNA template. The 100 µL reaction mix was dispensed
into the TLDA card chamber and centrifuged twice for 1 min at
1000 rpm to ensure the correct distribution of solution to each
well and removal of bubbles. Transcript expressionwas assessed
the by the comparative Ct approach relative to the endogenous
control genes IDH3B, GUSB and PPIA, which were selected based
upon empirical evidence for stability in response to treatment
and normalized to transcript expression in the untreated cells.
Assessment of alternative splicing in EndoC-βH1 cells
Of the panel of 31 genes selected for total gene expression,
17 were known to exhibit alternative splicing. Of these, 5 were
chosen for further analysis in EndoC-βH1 cells according to three
criteria: (i) unique, isoform-specific exon boundaries, (ii) known
functional differences between the isoforms and (iii) relevance
of isoform differences to beta cell differentiation status or islet
function. Isoforms of the INS, PAX6, POU5F1 (OCT4), NANOG and
PTPN1 genes fulfilled these criteria. Isoform-specific Taqman
custom assays (Thermo Fisher) were designed across unique
splice boundaries that distinguish between the functionally dis-
tinct isoforms. Probe and primer sequences are given in Supple-
mentary Material, Table S13.
Reversal of delta cell phenotype in EndoC-βH1 cells by
restoration of homeostasis
To test for reversibility of effect in our system, cells were first
treated with 25 mM glucose or 0.5 mM Tunicamycin for 24 h as
described above. Immediately following this, cells were restored
to normal culture conditions for 72 h prior to assessment of cell
identity, total gene expression and splicing patterns.
Reversal of delta cell phenotype in EndoC-βH1 cells by
restoration of homeostasis or by small molecule
inhibition of AKT pathway
Previous reports suggest that changes to beta cell identity can
be reversed upon removal of cellular stress (15). Reports have
suggested that the AKT pathway, one of the signalling mech-
anisms whereby cells can communicate signals from stimuli
such as cellular stress stimuli from the exterior of the cell, is
involved with regulation of splicing decisions and has also been
linked with changes in beta cell plasticity (17,25,26). To test for
reversibility of effect in our system, cells were first treated with
25 mM glucose or 0.5 mM Tunicamycin for 24 h as described
above. Immediately following this, cells were restored to normal
culture conditions for 72 h prior to assessment of cell identity,
total gene expression and splicing patterns. To assess the effect
of AKT inhibition on response to hyperglycaemia, cells were
treated with 25 mM glucose alone, 1 µM of the AKT inhibitor SH-
6 alone or 25 mM glucose in combination with 1 µM SH-6 for
24 h prior to assessment of splicing patterns and cell identity as
described above.
Whole transcriptome analysis of patterns of alternative
splicing in islets from human donors with T2D
compared with non-diabetic human islets
Weassessed patterns of total gene expression and transcriptome-
wide patterns of alternative splicing in an initial discovery
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set of six islets preparations from donors with T2D versus
six non-diabetic samples from the integrated islet distribution
programme using the ClariomD pico system (Thermo Fisher). A
subsequent validation set of six islets preparations from donors
with T2D versus six non-diabetic samples were also assessed to
validate results from the first islets set. All islets were matched
for age, gender and Body mass index (BMI). Sample preparation
and gene chip cartridge arrays were performed by UK Bioin-
formatics Ltd (Woldingham, Caterham, Surrey). Transcriptome
data for total gene and splicing expression were analysed using
TAC 4.0.2.10 (Applied Biosystems, Thermo Fisher). For both total
expression and splicing genes were filtered to remove non-
coding RNAs, pseudogenes and incompletely annotated genes.
Differentially expressed genes and dysregulated splicing events
with a P-value of <0.05 in both islets sets were taken forward
into pathways and GO analysis carried out using Enrichr (51,52).
Supplementary Material
Supplementary Material is available at HMG online.
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